Detragel® (Detragel®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspgel for external use
Composition:

1 g of gel contains:

Active substances:

Sodium Heparin 100.0 ME

Essential phospholipids 10.0 mg

Eszin 10.0 mg

Excipients: isopropanol 300.00 mg, glycerol 85% 20.00 mg, trolamine 10,80 mg, methyl parahydroxybenzoate 0.75 mg, ethylparahydroxybenzoate 0.75 mg, propyl parahydroxybenzoate 0.25 mg, carbomer 980 8.00 mg, cologne 0.70 mg, rosemary oil 0.40 mg, lavender oil 0.40 mg, water up to 1.00 g.

Description:Transparent, light-yellow gel with a characteristic odor.
Pharmacotherapeutic group:Venotonizing agent + anticoagulant direct action for topical application
ATX: & nbsp
  • Heparin in combination with other drugs
    • Pharmacodynamics:

    Combined drug, has a local anticoagulant, anti-inflammatory, venotonizing and antiaggregant effect, reduces the permeability of veins, improves microcirculation. Detragel® contains 3 active ingredients heparin sodium, essential phospholipids and escin, which have pharmacodynamic and pharmacokinetic synergy.

    Heparin sodium is an anticoagulant of direct action; due to the inactivation of biogenic amines and the blocking of lysosomal enzymes in tissues, exhibits an anti-inflammatory effect,accelerates the dissolution of microthrombi in the subcutaneous capillary region, prevents thrombus formation, activates the fibrinolytic system; improves microcirculation, promotes regeneration of connective tissue due to inhibition of hyaluronidase activity.

    Essential phospholipids reduce the viscosity of blood due to the effect on fat metabolism, reduce the process of platelet aggregation.

    Eszin is a venotonic agent of plant origin.

    Prevents the activation of lysosomal enzymes that break down proteoglycan, increases the tone of the venous wall, eliminates venous congestion; reduces permeability and fragility of capillaries. Reduces exudation, reduces the effusion of fluid in the tissue and speeds up the resorption of the existing edema. It inhibits the processes of inflammation, improves microcirculation, promotes tissue repair.

    Pharmacokinetics:

    Information on the pharmacokinetics of escin and phospholipids in external application is absent. Sodium Heparin when topically applied quickly penetrates through the epidermis and accumulates in the upper layers of the skin. A small amount of sodium heparin is absorbed from the surface of the skin into the systemic circulation (less than 0.2% of the total appliedquantity). The maximum concentration (CmOh) in the blood is noted 8 hours after the application. After absorption, biotransformed in the liver and in the reticuloendothelial system. Sodium Heparin is excreted mainly with urine. The half-life (T1/2) is 12 hours. Heparin does not penetrate the placental barrier and is not excreted in breast milk.

    Due to their own hydrophilic and lipophilic properties, essential phospholipids promote rapid penetration of active ingredients through the sebaceous and sweat glands, which was confirmed by tests with radioisotopes.

    Indications:

    - Therapy of symptoms of chronic diseases of veins;

    - Varicose illness with symptoms in the form of pain, swelling, sensation of heaviness and fatigue in the legs, night cramps of the calf muscles, and with signs in the form of telangiectasias (vascular sprouts and meshes) and varicose veins;

    - Superficial phlebitis, thrombophlebitis;

    - Hematomas with injuries, including sports sprains and bruises;

    - Postoperative hematomas without compromising the integrity of the skin.

    Contraindications:

    - Hypersensitivity to the components of the drug, hemorrhagic diathesis (incl.thrombocytopenic purpura), hemophilia, a violation of the integrity of the skin at the site of application (open wounds, ulcerative necrotic lesions), burns, eczema, skin infections

    - Contraindicated in mucous membranes

    - Age to 18 years.

    Pregnancy and lactation:

    To date, there have been no reports of adverse effects on the mother and fetus with the use of the drug by pregnant women.

    Application during pregnancy and during breastfeeding is possible only in cases where the expected benefit of therapy for the mother exceeds the potential risk to the fetus, so before using the drug should consult a doctor.

    Dosing and Administration:

    For external use.

    The gel is applied a thin layer on the problem area of ​​the skin and evenly distributed with light massaging movements: 2-3 times a day daily until the symptoms disappear. If necessary, the gel can be applied under elastic stockings or bandages. In thrombophlebitis, avoid rubbing the gel. Contraindicated application of the gel on the mucous membranes.

    Duration of treatment - no more than 15 days.

    If your condition worsens or the improvement does not occur after 15 days, you should consult a doctor. The possibility of a longer treatment is determined by the doctor.

    Do not exceed the recommended dose and duration of administration.

    Side effects:

    Side effects are given in the form of the following gradation: very often (≥1 / 10); often (≥1 / 100, <1/10); infrequently (≥1 / 1,000, <1/100); rarely (≥1 / 10,000, <1/1 000); very rarely (<1/10 000), unspecified frequency (frequency can not be calculated from available data).

    From the skin:

    Rarely: allergic reactions of delayed type (contact dermatitis)

    Rarely: allergic reactions of immediate type (skin rash, skin itching, urticaria)

    From the respiratory system, organs of the thorax and mediastinum:

    Rarely: bronchospasm.

    When topical application of escin was reported on single cases of development of acute anaphylactic reactions (see section "Special instructions").

    In case of side effects when using the drug should consult a doctor.

    Overdose:

    Data on drug overdose are absent.

    If an overdose occurs, consult a doctor immediately.

    Treatment: in the case of an overdose, the effect of heparin may be neutralized with a solution of protamine sulfate.

    Interaction:

    At the moment there is no data on the interaction with other drugs.

    The drug should not be applied to the same skin area simultaneously with other medicinal products for external use.

    Special instructions:

    The application of the gel to the mucous membranes is contraindicated. Avoid contact with eyes.

    In case of allergic reactions, the drug should be stopped immediately and consult a doctor.

    Medicines for topical application, especially after prolonged use, have a sensitizing effect. If this occurs, then the drug should be discontinued and, if necessary, appropriate treatment is prescribed. With prolonged use of the drug on large areas of the skin and simultaneous use of anticoagulants of indirect action (warfarin, acenocoumarol and others), prothrombin time and clotting time should be monitored.

    It is not recommended to use Detragel® for deep vein thrombosis.

    The experience of using the drug in children under the age of 18 is absent.

    If your condition worsens or the improvement does not occur after 15 days, you should consult a doctor.

    Effect on the ability to drive transp. cf. and fur:Studies on the study of the effect of the drug on the ability to drive a car and manage mechanisms have not been carried out.
    Form release / dosage:Gel for external use.
    Packaging:

    40.0 g per aluminum tube, sealed with a membrane and a screw cap made of polypropylene. The tube with instruction for use is placed in a cardboard box.

    Storage conditions:At a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:

    2 years. Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-001044
    Date of registration:21.10.2011 / 03.08.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:SERVICE, CJSC SERVICE, CJSC Russia
    Manufacturer: & nbsp
    BOSNALIJEK, d.d. Bosnia and Herzegovina
    Information update date: & nbsp15.03.2018
    Illustrated instructions
      Instructions
      Up